Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 6,301–6,400 of 15,747
Matson, R., Niesen, M. J. M., Levy, E. R., Opp, D. N., Lenehan, P. J., Donadio, G., O’Horo, J. C., Venkatakrishnan, A., Badley, A. D., & Soundararajan, V. (2023) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00253-9 · Cited by 13
Medium-term scenarios of COVID-19 as a function of immune uncertainties and chronic disease
Saad-Roy, C. M., Morris, S. E., Baker, R. E., Farrar, J., Graham, A. L., Levin, S. A., Wagner, C. E., Metcalf, C. J. E., & Grenfell, B. T. (2023) · Journal of The Royal Society Interface · doi:10.1098/rsif.2023.0247 · Cited by 14
Evaluating Vaccine Efficacy Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Lin, D.-Y., Gu, Y., Zeng, D., Janes, H., & Gilbert, P. B. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab630 · Cited by 14
Ahmed, M. I. M., Diepers, P., Janke, C., Plank, M., Eser, T. M., Rubio‐Acero, R., Fuchs, A., Baranov, O., Castelletti, N., Kroidl, I., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1026473 · Cited by 17
Area, I., Lorenzo, H., Marcos, P. J., & Nieto, J. J. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105104 · Cited by 12
“Given that the impact of vaccines where it has demonstrated the most efficacy is avoiding or reducing the risk of mortality or admission [24,25], it seems very reasonable to adopt a vaccination strategy by age.”
BackgroundQuantifying the Importance of COVID-19 Vaccination to Our Future Outlook
Storlie, C. B., Pollock, B. D., Rojas, R. L., Demuth, G., Johnson, P. W., Wilson, P. M., Heinzen, E. P., Liu, H., Carter, R. E., Habermann, E. B., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.04.012 · Cited by 13
Lineburg, K. E., Neller, M. A., Ambalathingal, G. R., Texier, L. L., Raju, J., Swaminathan, S., Lekieffre, L., Smith, C., Rehan, S., Crooks, P., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1326 · Cited by 16
Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20–22 April 2021
Suliman, S., Pelzer, P. T., Shaku, M. T., Rozot, V., & Mendelsohn, S. C. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.094 · Cited by 16
“Finally, Mustafa Diken (BioNTech, Germany) presented the benefits of the mRNA vaccine technology used for COVID-19 [12], and how it can be tailored for TB vaccinology using additional strategies such as self-amplifying RNA molecules [13].”
BackgroundKealy, L. C., & Good‐Jacobson, K. L. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab018 · Cited by 15
“With 196 million cases confirmed worldwide and 4.2 million lives lost as of July 2021, COVID-19 has fast become the most challenging pandemic of this century [2].”
BackgroundInfluentialOutcomes of breakthrough COVID-19 infections in patients with hematologic malignancies
Chien, K. S., Peterson, C. B., Young, E. J., Chihara, D., Manasanch, E. E., Ramdial, J., & Thompson, P. A. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008827 · Cited by 15
“051 Platelets, 10(3)/μL 177 (1-600) 162 (1-747) .”
Impact of multiple doses of vaccination on epidemiological spread in multiple networks
Li, L., Dong, G., Zhu, H., & Tian, L. (2024) · Applied Mathematics and Computation · doi:10.1016/j.amc.2024.128617 · Cited by 13
2019 Novel Coronavirus Vaccination among Post-graduate Residents and Fellows
Abohelwa, M., Elmassry, M., Abdelmalek, J., Payne, D., & NUGENT, K. M. (2021) · Journal of Primary Care & Community Health · doi:10.1177/21501327211022978 · Cited by 14
King, H. A. D., Joyce, M., Naouar, I. E., et al. (2021) · bioRxiv · doi:10.1101/2021.04.09.439166 · Cited by 5
Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Liu, J., Budylowski, P., Samson, R., Griffin, B., Babuadze, G., Rathod, B., Colwill, K., Abioye, J., Schwartz, J., Law, R., et al. (2021) · bioRxiv · doi:10.1101/2021.05.11.443286 · Cited by 51
The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What
Khong, K.-W., Zhang, R., & Hung, I. F. (2022) · Vaccines · doi:10.3390/vaccines10111924 · Cited by 16
“One possible explanation could be a higher vaccine dose, as one dose of mRNA-1273 contains 100 μg of active substance while one dose of the BNT162b2 vaccine contains 30 μg of active ingredient [61,62].”
BackgroundGallo, K., Goede, A., Mura, C., Abel, R., Moahamed, B., Preißner, S., Nahles, S., Heiland, M., Bourne, P. E., Preißner, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10030408 · Cited by 15
“Both the Pfizer/BioNTech and Moderna vaccines, which are each administered as two doses, rely on mRNA technology to encode the same spike protein, carried for delivery inside lipid nanoparticle capsules [2,3].”
BackgroundPapini, F., Grassi, N., Guglielmi, G., et al. (2021) · Environmental Health and Preventive Medicine · doi:10.1186/s12199-021-01018-z · Cited by 13
Corneal Complications after COVID-19 Vaccination: A Systemic Review
Huang, L., Chiang, C.-C., Li, Y., Lai, H., Hsieh, Y.-C., Wu, Y.-H., & Tsai, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226828 · Cited by 14
Zhou, Q., Zeng, F., Meng, Y., Liu, Y., Liu, H., Chen, X., & Deng, G. (2023) · Scientific Reports · doi:10.1038/s41598-023-37051-x · Cited by 14
What’s Next after Lipid Nanoparticles? A Perspective on Enablers of Nucleic Acid Therapeutics
Das, R., Kanjilal, P., Medeiros, J., & Thayumanavan, S. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00058 · Cited by 15
Omar, S. M., Khalil, R., Adam, I., & Al‐Wutayd, O. (2022) · Vaccines · doi:10.3390/vaccines10040527 · Cited by 16
Adrenomedullin Therapy in Moderate to Severe COVID-19
Kita, T., & Kitamura, K. (2022) · Biomedicines · doi:10.3390/biomedicines10030533 · Cited by 14
“and BioNTech SE was 95% effective in preventing COVID-19 [76].”
BackgroundSivaramakrishnan, P., & Mishra, M. K. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-249237 · Cited by 13
Using mortuary and burial data to place COVID-19 in Lusaka, Zambia within a global context
Sheppard, R. J., Watson, O. J., Pieciak, R. C., Lungu, J., Kwenda, G., Moyo, C., Chanda, S. L., Barnsley, G., Brazeau, N. F., Gerard-Ursin, I. C. G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39288-6 · Cited by 27
Yin, Q., Song, X., Yang, P., Yang, W., Li, X., Wang, X., & Wang, S. (2022) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2022.102649 · Cited by 18
Multiantigen pan-sarbecovirus DNA vaccines generate protective T cell immune responses
van Bergen, J., Camps, M. G. M., Pardieck, I. N., Veerkamp, D. M. B., Leung, W. Y., Leijs, A. A., Myeni, S. K., Kikkert, M., Arens, R., Zondag, G. C. M., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.172488 · Cited by 12
A data-driven epidemic model with human mobility and vaccination protection for COVID-19 prediction
Li, R., Song, Y., Qu, H., Li, M., & Jiang, G. (2023) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2023.104571 · Cited by 15
SARS-CoV-2 vaccines — the biggest medical research project of the 21st century
Kurup, D., & Schnell, M. J. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.04.008 · Cited by 14
“A recent phase 3 study with both vaccines indicated that both bestowed an exceptionally high protection level of about 95% in preventing symptomatic COVID-19 disease and 100% prevention of severe COVID-19 disease [15,16].”
Yoon, B. K., Oh, T. G., Bu, S., Seo, K. J., Kwon, S. H., Lee, J. Y., Kim, Y., Kim, J. W., Ahn, H., & Fang, S. (2022) · Molecules and Cells · doi:10.14348/molcells.2022.0031 · Cited by 13
“Fortunately, messenger RNA (mRNA)-based vaccines, which were developed less than a year after the start of the pandemic, confer 95% protection against SARS-CoV-2 infection (Arunachalam et al., 2021; Polack et al., 2020; Shah and Woo, 2021).”
BackgroundMarkers of Memory CD8 T Cells Depicting the Effect of the BNT162b2 mRNA COVID-19 Vaccine in Japan
Kondo, H., Kageyama, T., Tanaka, S., Tsukumo, S., Otsuka, K., Mashimo, Y., Onouchi, Y., Nakajima, H., & Yasutomo, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836923 · Cited by 13
“We selected the SARS-CoV-2 S 269 (YLQPRTFLL) pentamer to detect antigen-specific CD8 T cells in our study because, among several pentamers for HLA-A*0201, this pentamer is the most frequently able to detect antigen-specific T cells from COVID-19 patients 13 .”
BackgroundInfluentialTerao, T., Yamashita, T., Fukumoto, A., Kamura, Y., Ikeda, D., Kuzume, A., Tabata, R., Tsushima, T., Miura, D., Narita, K., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03300-4 · Cited by 14
Mathematical Modeling Evaluates How Vaccinations Affected the Course of COVID-19 Disease Progression
Tzamali, E., Sakkalis, V., Tzedakis, G., Spanakis, E. G., & Tzanakis, N. (2023) · Vaccines · doi:10.3390/vaccines11040722 · Cited by 13
Clinical characteristics in immune thrombocytopenia patients after COVID-19 vaccination
Feng, Y., Yao, Q., Cassady, K. M., Zou, Z., Gao, Y., & Zhang, X. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2119043 · Cited by 14
“The most common AEs are mild and include injection site reactions, fever, chills, fatigue, headache, and muscle and joint aches.(4,5) However, there are also reports of some rare complications, such as interstitial pneumonia(6) and immune thrombotic thrombocytopenia.”
BackgroundElslande, J. V., Weemaes, M., Godderis, L., Pottelbergh, G. V., Bossuyt, X., & Vermeersch, P. (2022) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2022.115638 · Cited by 15
Shiga, H., Kakuta, Y., An, K., Abe, Y., Fujimaki, S., Shimoyama, Y., Naito, T., Moroi, R., Kuroha, M., Khor, S., et al. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16001 · Cited by 13
Rare Heterogeneous Adverse Events Associated with mRNA-Based COVID-19 Vaccines: A Systematic Review
Oueijan, R. I., Hill, O. R., Ahiawodzi, P. D., Fasinu, P. S., & Thompson, D. K. (2022) · Medicines · doi:10.3390/medicines9080043 · Cited by 16
“Although not reported in the randomized controlled clinical trials for the newly developed mRNA vaccines [1,2], case reports and case series document a rare occurrence of the acute onset of myocarditis/pericarditis symptoms in close temporal proximity to mRNA COVID-19 vaccination.”
BackgroundInfluentialmRNA and Viral Vector COVID-19 Vaccines Do Not Affect Male Fertility: A Prospective Study
Massarotti, C., Stigliani, S., Maccarini, E., et al. (2022) · The World Journal of Men s Health · doi:10.5534/wjmh.220055 · Cited by 13
Blain, H., Tuaillon, É., Gamon, L., Pisoni, A., Miot, S., & Picot, M. (2022) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2022.02.006 · Cited by 13
“We compared IgG levels against the SARS-CoV-2 receptor-binding domain (RBD)-IgG) (1) after 2 doses of BNT162b2, (2) just before the third vaccine dose, and (3) after the third dose.”
Is border closure effective in containing COVID-19?
Timur, L., & Xie, Y. (2021) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2021.102137 · Cited by 15
Ruhl, L., Kühne, J. F., Beushausen, K., Keil, J., Christoph, S., Sauer, J., & Falk, C. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1120010 · Cited by 15
“Frontiers in Immunology 10 studies of mRNA- (1) and vector-based vaccine candidates (2) proved efficient induction of spike-specific humoral and cellular immune responses.”
BackgroundKumar, A., Tripathi, P., Kumar, P., Shekhar, R., & Pathak, R. (2024) · Vaccines · doi:10.3390/vaccines12050459 · Cited by 18
Hartley, G. E., Edwards, E. S. J., Varese, N. P., Boo, I., Aui, P. M., Bornheimer, S. J., Hogarth, P. M., Drummer, H. E., O’Hehir, R. E., & van Zelm, M. C. (2022) · Allergy · doi:10.1111/all.15624 · Cited by 10
Ftouh, M., Kalboussi, N., Abid, N., Sfar, S., Mignet, N., & Bahloul, B. (2021) · PPAR Research · doi:10.1155/2021/6741290 · Cited by 14
“The world’s leading vaccine approved in 55 countries is BioNTech/Pfizer’s LNP vaccine being the first ever RNA-based vaccine, licensed for human use with more than 90% efficacy [76].”
BackgroundSafety-Related Outcomes of Novel mRNA COVID-19 Vaccines in Pregnancy
Nakahara, A., Biggio, J., Elmayan, A., & Williams, F. B. (2022) · American Journal of Perinatology · doi:10.1055/a-1745-1168 · Cited by 15
COVID ‐19 vaccine‐associated organizing pneumonia
Yoshikawa, T., Tomomatsu, K., Okazaki, E., Takeuchi, T., Horio, Y., Kondo, Y., Oguma, T., & Asano, K. (2022) · Respirology Case Reports · doi:10.1002/rcr2.944 · Cited by 12
Lu-Culligan, A., Tabachnikova, A., Pérez-Then, E. N., Tokuyama, M., Lee, H. J., Lucas, C. G. D. O., Monteiro, V. S., Miric, M., Brache, V., Cochón, L., et al. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001506 · Cited by 14
“Even as more data accumulate supporting the safety of the mRNA COVID-19 vaccines in pregnant and nonpregnant individuals alike [12,13], public perception of the risk surrounding vaccination has been impacted by the rapid proliferation of numerous theories that lack confirmatory data or overtly misrepresent the current…”
BackgroundDevelopment of DNA and mRNA-LNP vaccines against an H5N1 clade 2.3.4.4b influenza virus
Leonard, R. A., Spurrier, M. A., Skavicus, S., Luo, Z., Heaton, B. E., Spreng, R. L., Hong, J., Yuan, F., & Heaton, N. S. (2025) · Journal of Virology · doi:10.1128/jvi.00795-25 · Cited by 17
“The mRNA-LNP platform is highly likely to be utilized for human H5N1 vaccines as they have already been proven to be highly effective during the COVID-19 pandemic response; they produce both humoral and cellular immune responses, resulting in protection rates of over 90% (14, 39, 40).”
Salleh, A., & Saad, M. Z. (2021) · Animals · doi:10.3390/ani11071876 · Cited by 18
Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines
Alesci, A., Gitto, M., Kotańska, M., Cascio, P. L., Miller, A., Nicosia, N., Fumia, A., & Pergolizzi, S. (2022) · Human Immunology · doi:10.1016/j.humimm.2022.08.004 · Cited by 15
“COVID‐19 at or after day 7 after the second dose, calculated after the evaluation of 170 confirmed cases of COVID‐19 among more than 36,000 participants ≥16 years, with a median of two months of follow‐ up after vaccination [103].”
Mahmoud, A. A. A., Georgakis, M., Valenzuela, L. R. M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062977 · Cited by 13
Unlocking the potential of RNA-based therapeutics in the lung: current status and future directions
Man, H. S. J., Moosa, V. A., Singh, A. N., Wu, L., Granton, J. T., Juvet, S., Hoang, C. D., & de Perrot, M. E. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1281538 · Cited by 15
Delbrück, M., Hoehl, S., Toptan, T., Schenk, B., Grikscheit, K., Metzler, M., Herrmann, E. M., & Ciesek, S. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.883724 · Cited by 12
“First COVID-19 vaccine studies found high efficacy in adults (Baden et al., 2020; Polack et al., 2020), but the elderly, especially with comorbidities and Edited by:”
BackgroundCOVID-19 vaccination hesitancy and safety among adult people with epilepsy in eastern China
Wang, S., Lv, J., He, C., Yang, Y., Zheng, Y., Ye, L. Y., Shen, C., Shen, C., Xu, S., Ding, Y., et al. (2022) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2022.108984 · Cited by 12
“7%) [22,23], and the rate was even lower than that of this study.”
ResultRay, D., Quijano, R. N., & Andricioaei, I. (2022) · Chemical Science · doi:10.1039/d2sc00534d · Cited by 13
Arashiro, T., Arima, Y., Kuramochi, J., Muraoka, H., Sato, A., Chubachi, K., Oba, K., Yanai, A., Arioka, H., Uehara, Y., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.021 · Cited by 14
Determining the Reliability of Rapid SARS-CoV-2 Antigen Detection in Fully Vaccinated Individuals
Poopalasingam, N., Korenkov, M., Ashurov, A., Strobel, J., Fish, I., Hellmich, M., Gruell, H., Lehmann, C., Heger, E., & Klein, F. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105119 · Cited by 16
Guo, F. Q., & Yang, X. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s325496 · Cited by 14
Chan, B. C.-L., Li, P., Tsang, M. S., Sung, J. C.-C., Kwong, K. W.-Y., Zheng, T., Hon, S. S.-M., Lau, C.-P., Cheng, W., Chen, F., et al. (2023) · Molecules · doi:10.3390/molecules28134996 · Cited by 15
“Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Perez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.”
MethodSelf-citationSivasankar, C., Hewawaduge, C., & Lee, J. H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.015 · Cited by 15
(2022) · doi:10.1101/2022.03.17.22272529 · Cited by 76
Danz, H., Dauner, A. L., Sharma, S., Babiceanu, M., Clark, N., Ontiveros, R. J., Amezquita, R. A., Zhilin-Roth, A., Reyes, E., Khoo, C., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01263-1 · Cited by 16
Shukla, P., Pandey, P., Prasad, B., Robinson, T., Purohit, R., D'Cruz, L. G., Tambuwala, M. M., Mutreja, A., Harkin, J., Singh, T., et al. (2022) · Apollo (University of Cambridge) · doi:10.17863/cam.80842 · Cited by 13
Feder, K. A., Patel, A. B., Vepachedu, V. R., Dominguez, C. E., Keller, E. N., Klein, L., Kim, C., Blood, T., Hyun, J. K., Williams, T. W., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab762 · Cited by 14
Stability Criterion for the Assembly of Core–Shell Lipid–Polymer–Nucleic Acid Nanoparticles
Paris, J. L., Gaspar, R., Coelho, F., Beule, P. D., & Silva, B. F. B. (2023) · ACS Nano · doi:10.1021/acsnano.3c07204 · Cited by 16
Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine
MacMillen, Z., Hatzakis, K., Simpson, A., Shears, M. J., Watson, F., Erasmus, J. H., Khandhar, A. P., Wilder, B. K., Murphy, S. C., Reed, S. G., et al. (2024) · npj Vaccines · doi:10.1038/s41541-023-00799-4 · Cited by 14
Methodological Analysis: Randomized Controlled Trials for Pfizer and Moderna COVID-19 Vaccines
Hallas, D. M., Spratling, R. G., & Fletcher, J. (2021) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2021.04.001 · Cited by 13
“Thus, we conducted a rigorous analysis using the RCT CASP tools for the two RCTs, Pfizer (Polack et al., 2020) and Moderna (Baden et al.”
Li, H., Granger, L. A., Raimi‐Abraham, B. T., Shattock, R. J., Makatsoris, C., & Forbes, B. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125796 · Cited by 17
Harnessing antiviral RNAi therapeutics for pandemic viruses: SARS-CoV-2 and HIV
Bowden-Reid, E., Moles, E., Kelleher, A. D., & Ahlenstiel, C. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01788-x · Cited by 16
“The successful clinical translation of one LNP-siRNA therapeutic [25] and two LNP-mRNA vaccines [ 3 , 4 ] has amyloidosis now utilize a GalNAc conjugate, with reduced (every 3 weeks versus every 3 months) and less-invasive (subcutaneous versus intravenous) dosing requirements than that of Patisiran…”
Chico-Sánchez, P., Gras-Valentí, P., Algado-Sellés, N., Jiménez-Sepúlveda, N. J., Vanaclocha, H., Peiró, S., Burgos, J. S., Berenguer, A., Navarro, D., & Sánchez–Payá, J. (2022) · Preventive Medicine · doi:10.1016/j.ypmed.2022.107237 · Cited by 12
Sherman, A. C., Crombie, J. L., Cheng, C., Desjardins, M., Zhou, G., Ometoruwa, O., Rooks, R., Senussi, Y., McDonough, M. M., Guerrero, L. I., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac417 · Cited by 15
“)—have demonstrated high efficacy and safety for the general population [1, 2], the humoral and cellular kinetics in patients with lymphoid malignancies have not been well described after a primary series (three doses).”
Gobeil, P., Pillet, S., Boulay, I., Charland, N., Lorin, A., Cheng, M. P., Vinh, D. C., Boutet, P., der Most, R. G. V., Roman, F. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34728-1 · Cited by 13
Passing the Test: A model-based analysis of safe school-reopening strategies
Bilinski, A., Salomon, J., Giardina, J., et al. (2021) · medRxiv · doi:10.1101/2021.01.27.21250388 · Cited by 3
Vaccination status among patients with the need for emergency hospitalizations related to COVID-19
Toker, İ., Toker, A. K., Özdemır, A. T., Çelik, İ., Bol, O., & Bülbül, E. (2022) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2022.01.067 · Cited by 12
Sengupta, S., Bhattacharyya, D., Kasle, G., Karmakar, S., Sahu, O., Ganguly, A., Addya, S., & Sarma, J. D. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.729622 · Cited by 13
Acute Meningoencephalitis after COVID-19 Vaccination in an Adult Patient with Rheumatoid Vasculitis
Senda, J., Ashida, R., Sugawara, K., & Kawaguchi, K. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8815-21 · Cited by 13
Simonetti, O., Rizzetto, G., Molinelli, E., Diotallevi, F., Radi, G., Cirioni, O., D’Errico, M. M., & Offidani, A. (2021) · Healthcare · doi:10.3390/healthcare9040401 · Cited by 12
Sayed, A. A. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7110375 · Cited by 14
Adamalysins in COVID-19 – Potential mechanisms behind exacerbating the disease
Dias, I. R. D. S. R., Cao, Z., & Kwok, H. F. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112970 · Cited by 18
Kawamura, T., Nakazawa, D., Nishio, S., et al. (2023) · Modern Rheumatology Case Reports · doi:10.1093/mrcr/rxac093 · Cited by 12
Advancements in viral vaccine development: from traditional to modern approaches
Kumar, A., Ahmad, F., Sah, B. K., Aljabali, A. A. A., Mishra, Y., & Mishra, V. K. (2025) · Exploration of Immunology · doi:10.37349/ei.2025.1003203 · Cited by 14
Kelly, E., Greenland, M., de Whalley, P., Aley, P., Plested, E., Singh, N., Koleva, S., Tonner, S., Macaulay, G., Read, R., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.06.007 · Cited by 12
“12 Although increased reactogenicity has been reported in those with previous SARS-CoV-2 infection, we found no clear difference in reactogenicity when stratified by serostatus.”
Potential benefits of delaying the second mRNA COVID-19 vaccine dosePreprint
Maier, B. F., Burdinski, A., Rose, A. H., Schlosser, F., Hinrichs, D., Betsch, C., Korn, L., Sprengholz, P., Meyer‐Hermann, M., Mitra, T., et al. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2102.13600 · Cited by 13
Glader, C., Jeitler, R., Wang, Y., Tetyczka, C., Zettl, M., Schlömer, M., Caisse, P., Mesite, S., Stephan, S., Bourgeaux, V., et al. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106928 · Cited by 19
Thrombotic Complications after COVID-19 Vaccination: Diagnosis and Treatment Options
Gütl, K., Raggam, R. B., & Gary, T. (2022) · Biomedicines · doi:10.3390/biomedicines10061246 · Cited by 11
“Notably, the mechanism behind thrombotic events after mRNA vaccination is different from the pathomechanism of VITT as observed after recombinant adenoviral vector vaccination [36,54,55].”
BackgroundSARS-CoV-2 transmission, vaccination rate and the fate of resistant strains
Rella, S. A., Kulikova, Y. A., Dermitzakis, E., & Kondrashov, F. A. (2021) · medRxiv · doi:10.1101/2021.02.08.21251383 · Cited by 6
Scutt, G., Cross, M., & Waxman, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-12591-w · Cited by 15
“(2), with n set to 1, along with the (now) known values of S1 , I1 and R1 , to determine S2 , I2 and R2 , and so on.”
BackgroundMethodInfluentialEffect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination
Flisiak, R., Pawłowska, M., Rogalska, M., Bociąga‐Jasik, M., Kłos, K., Piekarska, A., & Zarębska‐Michaluk, D. (2021) · Vaccines · doi:10.3390/vaccines9111325 · Cited by 11
“Discussion In a placebo-controlled study evaluating the long-term efficacy of the BNT162b2 vaccine, carried out after the publication of the registration study results, the effectiveness of the vaccine against COVID-19 at six months of follow-up was 91%, while that against severe disease was 97% [2,3].”
BackgroundSafety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink
Kenigsberg, T. A., Hanson, K. E., Klein, N. P., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.042 · Cited by 12
“In the Pfizer-BioNTech phase 3 clinical trial, it was noted that incidence of Bell’s palsy was higher in the vaccine group than in the placebo group [28].”
Does COVID-19 Vaccination Warrant the Classical Principle “ofelein i mi vlaptin”?
Doulberis, M., Papaefthymiou, A., Kotronis, G., Gialamprinou, D., Soteriades, E. S., Kyriakopoulos, A. M., Chatzimichael, E., Kafafyllidou, K., Liatsos, C. N., Chatzistefanou, I., et al. (2021) · Medicina · doi:10.3390/medicina57030253 · Cited by 15
van Harten, R. M., Veldhuizen, E. J. A., Haagsman, H. P., & Scheenstra, M. R. (2021) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2021.110369 · Cited by 13
Vaccination and Non-Pharmaceutical Interventions: When Can the UK Relax About COVID-19?Preprint
Moore, S., Hill, E. M., Tildesley, M. J., Dyson, L., & Keeling, M. J. (2021) · medRxiv · doi:10.1101/2020.12.27.20248896 · Cited by 15
Mendizábal, M., Ducasa, N., Benencio, P., Anders, M., Cairo, F. M., Barbero, M., Etcheves, P., Alter, A., Scarton, G., Abraldeṣ, J. G., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.2034 · Cited by 11
“Different platforms of Covid19 vaccines have proved successful in the development of humoral response and consequently in the prevention of severe forms and reduction of mortality in the general population.[4,5] Knowledge on a vaccine- induced humoral response in SOT recipients is mostly limited and restricted to mess…”
BackgroundD’Auria, D., Fulgione, L., Romeo, V., et al. (2021) · Clinical and Translational Imaging · doi:10.1007/s40336-021-00441-0 · Cited by 12
Zaccardelli, A., Wallace, Z. S., & Sparks, J. A. (2023) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000930 · Cited by 14
“SARS-CoV-2 vaccines reduce COVID-19 risk and severity [25,26], even among those who are immunocompromised [27 && ].”
BackgroundA clustering and graph deep learning-based framework for COVID-19 drug repurposing
Bansal, C., Deepa, P. R., Agarwal, V., & Chandra, R. (2024) · Expert Systems with Applications · doi:10.1016/j.eswa.2024.123560 · Cited by 18
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.